gemcitabine + cisplatin + methylprednisolone

GEM-P is a **chemotherapy combination regimen** comprising **gemcitabine**, **cisplatin**, and **methylprednisolone**. It is primarily used as a **salvage therapy for relapsed or refractory Hodgkin’s and non-Hodgkin’s lymphoma**. Gemcitabine is a nucleoside analog that inhibits DNA synthesis, leading to cell death. Cisplatin is a platinum-based compound that binds to DNA and causes cross-linking, thus preventing replication and transcription. Methylprednisolone is a corticosteroid that exerts anti-inflammatory and immunosuppressive effects and plays a supportive role in the regimen. The combination leverages the synergistic cytotoxicity of gemcitabine and cisplatin, with methylprednisolone reducing inflammation and mitigating some chemotherapy side effects[2][4].

Brand names

GEM-P

Other names

gemcitabine, cisplatin and methylprednisoloneGEM-P regimen